<DOC>
	<DOCNO>NCT02052804</DOCNO>
	<brief_summary>The objective study : 1 ) design new diagnostic criterion use accurately define heart failure preserve ejection fraction ( HFpEF ) ; 2 ) good define risk factor associate HFpEF ; 3 ) elucidate clinical , cellular molecular mechanism involve development progression HFpEF ; 4 ) design test new therapeutic strategy patient HFpEF .</brief_summary>
	<brief_title>Understanding Treating Heart Failure With Preserved Ejection Fraction : Novel Mechanisms , Diagnostics Potential Therapeutics</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Coal Tar</mesh_term>
	<criteria>Group 1 No clinically overt heart failure Group 2 Known coronary artery disease Group 3 Known heart failure preserve ejection fraction Group 4 Known heart failure reduce ejection fraction Group 5 Healthy agematched control Age &lt; 18 year Known malignancy expect survival &lt; 1 year Pregnant recent pregnancy &lt; 6 month Recent event ( &lt; 2 week since Acute Coronary Syndrome , Heart failure admission Severe mitral aortic stenosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>